Triptorelin doesn't avert early ovarian failure in lymphoma

Triptorelin doesn't avert early ovarian failure in lymphoma
Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure, according to a study published online Nov. 5 in the Journal of Clinical Oncology.

(HealthDay)—Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist (GnRHa) triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure (POF), according to a study published online Nov. 5 in the Journal of Clinical Oncology.

Isabelle Demeestere, M.D., Ph.D., of the Université Libre de Bruxelles in Belgium, and colleagues conducted a one-year follow-up of a multicenter, randomized, prospective trial involving 84 patients with lymphoma, aged 18 to 45 years of age, to assess the efficacy of the GnRHa triptorelin plus norethisterone versus norethisterone alone in preventing chemotherapy-induced ovarian failure.

The researchers found that after six months of follow-up there was no difference between the groups in the mean follicle stimulating hormone values. After one year, there was no significant difference in the rate of POF between the GnRHa and control groups (20 and 19 percent, respectively). Ovarian function was completely restored for more than half the patients in each group, and higher anti-Müllerian hormone values were seen in the GnRHa group versus the . were similar between the groups, except for metrorrhagia, which was seen more often in the GnRHa group.

"In conclusion, this prospective study involving patients with did not provide evidence that GnRHa is effective in preventing POF," the authors write. "However, it suggests a long-term benefit of GnRHa on fertility of patients who spontaneously experience restoration of ovarian function. Until long-term results confirm the benefit of GnRHa to improve future fertility, the treatment should not be administered to prevent POF apart from in experimental protocols."

One author disclosed financial ties to Ipsen.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Life span of ovarian grafts longer than expected

Jun 28, 2012

Transplanting previously frozen ovarian tissue back into female cancer survivors can lead to long-term hormonal function and preservation of fertility, according to a new study by Samuel Kim from the University of Kansas ...

Socioeconomic class and smoking linked to premature menopause

Jul 06, 2011

Women from the lowest social class are almost three times as likely to have premature ovarian failure as those from the highest social class, a researcher told the annual conference of the European Society of Human Reproduction ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.